Hysteroscopy is an exploratory method for visualising the uterine cavity. In recent years, it has become an indispensable diagnostic and therapeutic technique in gynaecology. Due to its very high sensitivity, hysteroscopy allows a more conservative management of uterine pathology. The risk of a uterine malignancy increases with the age of the patient and in the presence of vaginal bleeding. Hysteroscopy has become the gold standard for the diagnosis of endometrial carcinoma. We have also recently found in the literature an increasing number of sarcomas diagnosed by hysteroscopy. Surgical hysteroscopy makes accurate histological diagnosis possible, which in turn facilitates appropriate surgical intervention. In the absence of a previous diagnosis, a second surgical intervention may be required in order to complete the treatment. Hysteroscopy may also facilitate the early diagnosis of uterine malignancies and could improve the prognosis of these patients.
Share this Article
Related Content In Gynaecological Oncology
Maintenance Treatment for Recurrent Ovarian Carcinoma – Evidence Supporting the Efficacy and Safety of PARP Inhibitors
European Oncology & Haematology. 2019;15(1):29–40 DOI: https://doi.org/10.17925/EOH.2019.15.1.29
Worldwide, ovarian cancer is the seventh most common cancer and the eighth most common cause of cancer death in women.1 The GLOBOCAN study estimated there were 239,000 new cases in 2012 and 152,000 deaths due to this disease. There are nearly 600,000 women living within 5 years of an ovarian cancer diagnosis.1 In the EU, age-adjusted ovarian […]
Advances in the Treatment of Endometrial and Ovarian Cancer
Oncology & Hematology Review. 2019;15(1):23–4 DOI: https://doi.org/10.17925/OHR.2019.15.1.23
Gynecological malignancies can be difficult to treat. Ovarian cancer carries with it the worst prognosis of all gynecological cancers. Approximately 75% of patients with epithelial ovarian cancer are diagnosed with advanced disease which is curable only in a minority of cases, resulting in a 5-year overall survival rate of only 20–30%. However, survival at all […]
The Belarus Experience of Pelvic Artery Embolisation in Patients with Advanced and Recurrent Cervical Cancer Presenting with Haemorrhage
European Oncology & Haematology, 2018;14(1):45–49 DOI: https://doi.org/10.17925/EOH.2018.14.1.45
Cervical cancer (CC) is a leading cause of cancer morbidity in women globally. In Europe, epidemiological data on CC incidence shows important differences between countries: from 3.6 per 100,000 women in Switzerland to 28.6 per 100,000 in Romania.1,2 In 2015 in the Republic of Belarus, the morbidity and mortality rate from CC were 11.9 and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!